Skip to main content
Terug
Watch Compare

InMed Pharmaceuticals Inc.

Datakwaliteit: 100%
INM
Nasdaq Manufacturing Chemicals
€ 0,72
▲ € 0,07 (11,20%)
Marktkapitalisatie: 1,88 M
Prijs
€ 0,64
Marktkapitalisatie
1,88 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -7,42 M
Capital efficient — spends only 0,00% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)7,50%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-72,38%
Onder sectorgemiddelde (-53,53%)
ROICN/A
Net Margin-170,07%
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio5,94
Interest CoverageN/A

Waardering

PE (TTM)
-0,25
Boven sectorgemiddelde (-1,48)
P/B Ratio0,20
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1366 peers)
Metriek Aandeel Sector Mediaan
P/E -0,3 -1,5
P/B 0,2 1,6
ROE % -72,4 -53,5
Net Margin % -170,1 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2026 — 8,18 M —

All Fundamental Metrics
Growth
Revenue Growth (1Y) 7,50% Revenue Growth (3Y) 9,32%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 4,51 M Net Income (TTM) -7,66 M
ROE -72,38% ROA -62,43%
Gross Margin 29,73% Operating Margin N/A
Net Margin -170,07% Free Cash Flow (TTM) -7,42 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5,94
Interest Coverage N/A Asset Turnover 0,37
Working Capital 7,31 M Tangible Book Value 8,05 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,25 Forward P/E N/A
P/B Ratio 0,20 P/S Ratio 0,42
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -394,85%
Market Cap 1,88 M Enterprise Value -5,08 M
Per Share
EPS (Diluted TTM) -2,88 Revenue / Share 1,54
FCF / Share -2,54 OCF / Share -2,54
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,00% FCF Conversion 96,84%
SBC-Adj. FCF -7,52 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4,94 M 4,60 M 4,14 M 1,09 M —
Net Income -8,16 M -7,68 M -7,95 M -18,60 M -10,20 M
EPS (Diluted) -8,36 -1,01 -3,25 -33,17 —
Gross Profit 1,71 M 1,10 M 1,40 M 543.546,0 —
Operating Income — — -7,95 M -18,60 M —
EBITDA — — — — —
R&D Expenses 2,85 M 3,77 M 3,73 M 7,28 M 5,34 M
SG&A Expenses — — — — —
D&A 212.839,0 219.600,0 202.249,0 185.657,0 120.866,0
Interest Expense — — — -360.350,0 —
Income Tax 7.100,0 7.100,0 13.100,0 — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 15,58 M 11,82 M 14,11 M 12,79 M 9,78 M
Total Liabilities 2,15 M 2,62 M 2,02 M 3,71 M 2,40 M
Shareholders' Equity 13,43 M 9,21 M 12,09 M 9,08 M 7,38 M
Total Debt — — — — —
Cash & Equivalents 11,08 M 6,57 M 8,91 M 6,18 M 7,36 M
Current Assets 12,87 M 8,69 M 11,33 M 9,60 M 8,38 M
Current Liabilities 1,84 M 1,97 M 2,00 M 3,32 M 2,22 M